Three groups comprising a total of 145 adult men were included in this prospective cross-sectional investigation. Sixty-one hypogonadal patients on testosterone or human chorionic gonadotrophin (hCG) substitution therapy (means^S.D.; age 35:3^11:6 years) formed group 1; of these, 16 men were treated with hCG (500–5000 IU twice a week; Schering, Berlin, Germany) and 45 with injectable, oral or transdermal testosterone (testosterone enanthate, 250 mg …n ˆ 35; Schering), oral testosterone undecanoate, 120 mg/day …n ˆ 3; Organon, Oberschleißheim, Germany) or daily transdermal testosterone patch …n ˆ 7; Ferring, Kiel, Germany)). All patients received substitution therapy for at least 12 months. Twenty-two patients with primary hypogonadotropic hypogonadism (age 32:7^ 12:0 years) and 39 patients with hypogonadism (age 36:7^11:2 years; 26 patients with idiopathic hypogonadism or Kallmann’s syndrome and 13 patients with hypopituitarism) were recruited for the study
Group 2 consisted of 24 newly diagnosed hypogonadal patients without previous androgen treatment (age 37:0^12:4 years; 15 with primary (age 40:9^11:7 years) and 9 with secondary hypogonadism (age 30:4^ 15 years)). The cause of hypogonadism was known in all patients in groups 1 and 2; patients attending our clinic for age-related reduced testosterone serum levels were excluded.
Group 3 was comprised of 60 unselected normal men (age 45:6^16:6 years) recruited from the general population. The younger men …n ˆ 31† were volunteers for clinical studies on male contraception (20–22). None reported any previous sex hormone treatment, no concomitant medication potentially interfering with sex hormones or body composition was allowed. All measurements were performed during the screening phase of the trial to avoid a positive selection through inclusion criteria. The older men …n ˆ 29† were recruited from the community by personal contacts. As with advancing age an increasing proportion of men have testosterone serum levels in the hypogonadal range, we did not exclude men with hypogonadal testosterone serum levels when no clinical evidence for the hypogonadism was seen. In all study groups, patients and/or volunteers with chronic diseases or medications which might interfere with sex hormones and body composition were excluded (e.g. patients under high-dose corticosteroid treatment or patients with a history of antineoplastic therapy). In the groups of hypogonadal men, only men with physiologic hormone replacement therapy were included. As growth hormone influences body composition and sex hormone production, hypogonadal patients on growth hormone substitution were excluded.
Morning blood samples for hormone analysis were drawn between 0800 and 1100 h. In patients treated with transdermal testosterone patches …n ˆ 7† or oral testosterone undecanoate …n ˆ 3†; blood was taken 3–6 h after administration. In patients given intramuscular testosterone enanthate …n ˆ 35†; blood was preferentially collected during the second week after application. In hCG-treated patients …n ˆ 16†; blood was obtained 2 days after injection.
Testosterone was determined by highly specific solidphase,
two-site fluoroimmunometric assay (AutoDELFIA Testosterone;
Wallac ADL-GmbH, Freiburg, Germany). The detection limit
was 0.469 nmol/l. The intra- and interassay coefficients
of variation were 5.8% and 10.8% respectively. Oestradiol
was measured by solid-phase immunofluoroassay (AutoDELFIA
Estradiol; Wallac ADL-GmbH). The detection limit for oestradiol
was 12.7 pmol/l. The intra- and interassay coefficients of variation for oestradiol were 6.6% and 8.1% respectively. Sex hormone-binding globulin (SHBG)was determined by a specific fluoroimmunoassay (DELFIA SHBG; Wallac ADL-GmbH). The intra- and interassay coefficients of variation for SHBG were 4.9% and 7.2% respectively. The normal range for SHBG is 11–71nmol/l. Serum levels of leptin were measured by radioimmunoassy (Linco Research Inc., St Charles, MO, USA). The detection limit was 0.5mg/l. The intra- and interassay coefficients of variation for leptin were 5.2 and 6.0% respectively. Bioactive unbound testosterone was calculated according to the method established by Vermeulen et al. (23).
Percent body fat mass was assessed by bioelectrical impedance using a multiple frequence bioimpedance analyser (Data Input, Frankfurt/Main, Germany) with 506 C Rolf and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 146 www.eje.org four cutaneous electrodes attached to specific sites of the dorsal surface of the hand and anterior surface of the ipsilateral foot. Bioelectrical impedance is based upon the conductivity of the human body, which depends on the relationship between fat and lean tissue. For total fat mass, the intra-individual coefficient of variance based on 13 repeated measurements by one single clinician was 2.3% and the inter-individual coefficient of variance based on duplicated measurement of adipose …n ˆ 3† and normal …n ˆ 4† volunteers by two independent clinicians was 6.1%. BMI was calculated by dividing body weight (kg) by square height (m).
Normal distribution of all hormone variables was tested by the Kolmogorov–Smirnov test and logarithmic transformation was performed when applicable. Bivariate correlation analysis was performed using age, anthropometric data and the various hormonal parameters. Two-sided P , 0:05 was considered significant.
Multiple regression analysis was applied for evaluation of joint effects of age, sex hormones, SHBG and leptin on BMI and body fat mass. Due to the small sample size, multiple regression analysis was not performed in group 2. Computations were performed using the statistical software package SPSS version 10.0 for Windows (Chigaco, IL, USA). Unless otherwise stated, results are given as means^S.D.
In group 1, no significant differences were found between patients with primary or secondary hypogonadism for any of the investigated variables; therefore, the two subgroups were combined to increase statistical power.
In group 1, no significant changes in BMI or body fat content were observed with advanced age and no age-related changes in serum testosterone levels were seen (Fig. 1). Oestradiol and SHBG serum levels also remained unchanged (Table 1). No decline in leptin serum levels was seen with advanced age; a strong association between leptin serum levels and BMI, body fat content, bioactive testosterone and SHBG was noted.
In the untreated hypogonadal men (group 2), an increase in body fat content, BMI and leptin was observed with increasing age (Table 2). Leptin serum levels were positively associated with BMI and body fat content. No associations between sex hormones or SHBG and anthropometric data were noted. In healthy men (group 3), a significant increase in BMI and body fat content was observed with advanced age. Serum testosterone levels decreased with advanced age …r ˆ 20:71; P , 0:001†: Increased serum leptin and SHBG levels were found in men of advanced age (Table 3). No associations between oestradiol and age or any anthropometric variable were found.
In treated hypogonadal men and in normal volunteers (groups 1 and 3), stepwise linear regression using leptin, testosterone, SHBG, oestradiol and age as the independent variables, showed BMI and body fat content were highly significantly associated with elevated leptin levels …P , 0:001†: Only in the group of unselected volunteers did the variable age show a slight but significant …P ˆ 0:034† additional association with BMI. All sex hormones investigated were excluded from this model.
In this cross-sectional study, we investigated age-dependent changes in BMI, body fat content and sex hormones in normal healthy men as well as androgensubstituted hypogonadal men. In normal men and even more so in untreated hypogonadal men, an increase in BMI and percentage of body fat was observed with advancing age. In addition, serum testosterone levels decreased in parallel in normal replacement therapy no decrease in testosterone serum levels was observed with advancing age. A slight increase in body mass, but no significant increase in the percentage of body fat is noted in these patients.
According to the results of the multiple linear regression analysis we cannot conclude which variable, declining testosterone serum levels or age per se, is responsible for the increase in BMI and body fat content in normal men, as there is a strong and highly significant interdependency between these variables. However, in hypogonadal patients receiving adequate testosterone substitution, where the regulating variable testosterone remains virtually unchanged with increasing age, no change in BMI and body fat content could be observed, indicating that the decline in sex hormones has an essential influence on the ‘physiologic’ increase in BMI and body fat content.
Leptin may be the main mediator of the influence of sex hormones on adipocytes: testosterone has been found to suppress leptin synthesis by adipocytes both in vivo and in vitro (24). In healthy normal men, suppression of endogenous testosterone production with gonadotrophin-releasing hormone (GnRH) agonists (25) or GnRH antagonists (26) results in an increase of leptin serum levels and, vice versa, testosterone administration to normal healthy men results in reduced leptin serum levels (25). Testosterone substitution therapy of hypogonadal men normalises elevated leptin serum levels (27).
It has been proposed that obesity in humans may be caused by resistance to leptin (28). However, the control of leptin secretion in humans is not well understood. Leptin has been proposed as the key link between energy stores and nutritional stores and the reproductive axes (29–31). Our data confirm the strong association between leptin and testosterone as well as between leptin and BMI and body fat content.
Studies on age-dependent changes of serum oestrogens give conflicting results (3, 12, 32–34). Lower testosterone levels and higher SHBG levels can intensify the influence of oestrogens on the organism, which may explain the increased incidence of gynaecomastia in senescent men (35). Our present data fail to indicate a decline of serum oestradiol levels with age in any group; moreover, no correlation between oestradiol serum levels and BMI or body fat content could be observed, indicating that oestradiol has no predominant influence on body composition in men. This is somewhat surprising, as it is generally accepted that testosterone is aromatised into oestradiol in adipose tissue and, thus, oestradiol serum levels should be elevated in adipose men. However, other studies also fail to correlate adiposity and oestradiol serum levels in men (4, 31, 36, 37).
From puberty onwards, males and females differ in bodily distribution of adipose tissue. Subcutaneous fat largely disappears in normal weight pubertal boys. From the age of 20–30 years on, men have approximately twice as much visceral fat storage as women with comparable BMI. Men preferentially store fat intra-abdominally, while premenopausal women usually store fat subcutanously on hips and thighs. The fact that ndrogens are involved in this sex-specific fat distribution has become increasingly clear, although the precise mechanism remains unknown.
Administration of testosterone induces changes in body composition, namely, an increase in both bone density and lean body mass and a decrease in fatty tissue. However, the process by which body composition affects the secretion of testosterone is highly controversial. Disease states such as obesity and chronic hypercortisolism are associated with increased adiposity and/or the central distribution of fat. Aging, characterised by excess adiposity, is also associated with impaired secretion of testosterone. In these states, both spontaneous and stimulated secretion of testosterone are severely impaired. Interestingly, in women the opposite relationship between androgens and obesity is present: testosterone is positively correlated with BMI and leptin levels (38–40). Nevertheless, it is not known whether obesity causes hyperandrogenaemia or hyperandrogenaemia causes obesity in women.
Testosterone not only has anabolic effects but this steroid and its metabolites, oestradiol and dihydrotestosterone, also have psychotropic effects (41). As well as improving libido in hypogonadal men, testosterone administration also results in increased general well-being and physical/mental activity. Although no direct measurement of lean body mass was performed and we cannot exclude the possibility that the reduced body fat content was caused by increased physical activity of testosterone-treated men, our data document that testosterone substitution can be beneficial for ageing hypogonadal men, at least with regard to body composition.
We are grateful to Nicole Terwort and Martina Niemeier for technical assistance and Susan Nieschlag for editing the manuscript.
1. Harman SM, Metter EJ, Tobin JD, Pearson
J & Blackman MR.
Longitudinal effects of aging on serum total and free testosterone
levels in healthy men. Baltimore Longitudinal Study of Aging.
Journal of Clinical Endocrinology and Metabolism 2001 86
2. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL
et al. Changes in serum concentrations of conjugated and unconjugated
steroids in 40- to 80-year-old men. Journal of Clinical
Endocrinology and Metabolism 1994 79 1086–1090.
3. Gray A, Feldman HA, McKinlay JB & Longcope C. Age, disease,
and changing sex hormone levels in middle-aged men: resultsof the
Massachusetts Male Aging Study. Journal of Clinical
Endocrinology and Metabolism 1991 73 1016–1025.
4. Leifke E, Gorenoi V, Wichers C, Von Zur Mu¨ hlen A, Von Bu¨ ren E &
Brabant G. Age-related changes of serum sex hormones, insulinlike
growth factor-1 and sex-hormone binding globulin levels in
men: cross-sectional data from a healthy male cohort. Clinical
Endocrinology 2000 53 689–695.
5. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M,
Nahoul K et al. The influence of aging on plasma sex hormones
in men: the Telecom Study. American Journal of Epidemiology
1992 135 783–791.
6. Vermeulen A & Kaufman JM. Ageing of the hypothalamo–
pituitary–testicular axis in men. Hormone Research 1995 43
7. Vermeulen A, Goemaere S & Kaufman JM. Testosterone, body
composition and aging. Journal of Endocrinological Investigation
1999 22 110–116.
8. Marin P. Testosterone and regional fat distribution. Obesity
Research 1995 3 (Suppl 4) 609S–612S.
9. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI,
Anderson EJ & Klibanski A. Increase in bone density and lean
body mass during testosterone administration in men with
acquired hypogonadism. Journal of Clinical Endocrinology and
Metabolism 1996 81 4358–4365.
10. Marin P & Arver S. Androgens and abdominal obesity. Bailliere’s
Clinical Endocrinology and Metabolism 1998 12 441–451.
11. Haffner SM, Miettinen H, Karhapaa P, Mykkanen L & Laakso M.
Leptin concentrations, sex hormones, and cortisol in nondiabetic
men. Journal of Clinical Endocrinology and Metabolism 1997 82
12. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V
et al. Association between plasma total testosterone and cardiovascular
risk factors in healthy adult men: the Telecom Study.
Journal of Clinical Endocrinology and Metabolism 1997 82
13. Janssen YJ, Frolich M, Deurenberg P & Roelfsema F. Serum
leptin levels during recombinant human GH therapy in adults
with GH deficiency. European Journal of Endocrinology 1997
14. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G et al.
The effects of testosterone treatment on body composition and
metabolism in middle-aged obese men. International Journal of
Obesity and Related Metabolic Disorders 1992 16 991–997.
15. Behre HM, von Eckardstein S, Kliesch S & Nieschlag E. Long-term
substitution therapy of hypogonadal men with transscrotal testosterone
over 7–10 years. Clinical Endocrinology 1999 50
16. Behre HM, Kliesch S, Leifke E, Link TM & Nieschlag E. Long-term
effect of testosterone therapy on bone mineral density in hypogonadal
men. Journal of Clinical Endocrinology and Metabolism
1997 82 2386–2390.
17. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B,
Phillips J et al. Testosterone replacement increases fat-free mass
andmuscle size in hypogonadalmen. Journal of Clinical Endocrinology
and Metabolism 1997 82 407–413.
18. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P & Ross C.
Testosterone replacement in older hypogonadal men: a 12-month
randomized controlled trial. Journal of Clinical Endocrinology and
Metabolism 1997 82 1661–1667.
19. Nieschlag E & Behre HM. Testosterone therapy. In Andrology: Male
Reproductive Health and Dysfunction, edn 2, pp 2311–2326. Eds E
Nieschlag & HM Behre. Berlin, Heidelberg, New York: Springer,
20. Kamischke A, Ploger D, Venherm S, von Eckardstein S, von
Eckardstein A & Nieschlag E. Intramuscular testosterone undecanoate
with or without oral levonorgestrel: a randomized
placebo-controlled feasibility study for male contraception. Clinical
Endocrinology 2000 53 43–52.
21. Kamischke A, Venherm S, Ploger D, von Eckardstein S &
Nieschlag E. Intramuscular testosterone undecanoate and
norethisterone enanthate in a clinical trial for male contraception.
Journal of Clinical Endocrinology and Metabolism 2001 86
22. Kamischke A, Diebacker J & Nieschlag E. Potential of norethisterone
enanthate for male contraception: pharmacokinetics and
suppression of pituitary and gonadal function. Clinical Endocrinology
2000 53 351–358.
23. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of
simple methods for the estimation of free testosterone in serum.
Journal of Clinical Endocrinology and Metabolism 1999 84
24. Kiess W, Reich A, Meyer K, Glasow A, Deutscher J, Klammt J et al.
A role for leptin in sexual maturation and puberty? Hormone
Research 1999 51 (Suppl S3) 55–63.
25. Hislop MS, Ratanjee BD, Soule SG & Marais AD. Effects of anabolic-
androgenic steroid use or gonadal testosterone suppression
on serum leptin concentration in men. European Journal of
Endocrinology 1999 141 40–46.
26. Bu¨ chter D, Behre HM, Kliesch S, Chirazi A, Nieschlag E, Assmann
G et al. Effects of testosterone suppression in young men by the
gonadotropin releasing hormone antagonist cetrorelix on
plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin,
and leptin. Experimental and Clinical Endocrinology and Diabetes
1999 107 522–529.
27. Jockenho¨vel F, Blum WF, Vogel E, Englaro P, Mu¨ ller-Wieland D,
Reinwein D et al. Testosterone substitution normalizes elevated
serum leptin levels in hypogonadal men. Journal of Clinical
Endocrinology and Metabolism 1997 82 2510–2513.
28. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL & Considine RV.
Leptin: the tale of an obesity gene. Diabetes 1996 45
29. Baumgartner RN, Waters DL, Morley JE, Patrick P, Montoya GD &
Garry PJ. Age-related changes in sex hormones affect the sex
difference in serum leptin independently of changes in body fat.
Metabolism 1999 48 378–384.
30. Behre HM, Simoni M & Nieschlag E. Strong association between
serum levels of leptin and testosterone in men. Clinical Endocrinology
1997 47 237–240.
31. Isidori AM, Strollo F, More M, Caprio M, Aversa A, Moretti C et al.
Leptin and aging: correlation with endocrine changes in male
and female healthy adult populations of different body weights.
Journal of Clinical Endocrinology and Metabolism 2000 85
32. Vermeulen A, Kaufman JM & Giagulli VA. Influence of some biological
indexes on sex hormone-binding globulin and androgen
levels in aging or obese males. Journal of Clinical Endocrinology
and Metabolism 1996 81 1821–1826.
33. Denti L, Pasolini G, Sanfelici L, Benedetti R, Cecchetti A, Ceda GP
et al. Aging-related decline of gonadal function in healthy men:
correlation with body composition and lipoproteins. Journal of
the American Geriatrics Society 2000 48 51–58.
34. Leifke E, Ko¨rner HC, Link TM, Behre HM, Peters PE & Nieschlag E.
Effects of testosterone replacement therapy on cortical and trabecular
bone mineral density, vertebral body area and paraspinal
muscle area in hypogonadal men. European Journal of Endocrinology
1998 138 51–58.
35. Rolf C & Nieschlag E. Potential adverse effects of long-term testosterone
therapy. Bailliere’s Clinical Endocrinology and Metabolism
1998 12 521–534.
36. Garaulet M, Perex-Llamas F, Fuente T, Zamora S & Tebar FJ.
Anthropometric, computed tomography and fat cell data in an
obese population: relationship with insulin, leptin, tumor necrosis
factor-alpha, sex hormone-binding globulin and sex hormones.
European Journal of Endocrinology 2000 143 657–666.
37. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli
Labate AM, Fabbri R et al. Effect of obesity and body fat distribution
on sex hormones and insulin in men. Metabolism 1991
38. Bjorntorp P. Hyperandrogenicity in women – a prediabetic
condition? Journal of Internal Medicine 1993 234 579–58339 Mantzoros CS,
Dunaif A & Flier JS. Leptin concentrations in the
polycystic ovary syndrome. Journal of Clinical Endocrinology and
Metabolism 1997 82 1687–1691.
40. Rouru J, Anttila L, Koskinen P, Penttila TA, Irjala K, Huupponen R
et al. Serum leptin concentrations in women with polycystic ovary
syndrome. Journal of Clinical Endocrinology and Metabolism 1997
41. Zitzmann M & Nieschlag E. Testosterone levels in healthy men
and the relation to behavioural and physical characteristics:
facts and constructs. European Journal of Endocrinology 2001
Received 23 August 2001
Accepted 18 January 2002